MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...

At first, the pain is worst during activity and may be absent when not training. As the problem worsens, the localized pain is present with all activity and often even at rest. The player is ...

MIRA Pharmaceuticals (MIRA) announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain.